Clinical trial
A Randomized, Double-blinded, Placebo-controlled, Dose-escalation Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetic of LPM3770164 Sustained-release Tablets in Healthy Subjects
NCT05238701 is registered in ClinicalTrials.gov with Luye Pharma Group Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-blinded, Placebo-controlled, Dose-escalation Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetic of LPM3770164 Sustained-release Tablets in Healthy Subjects
- Lead sponsor
- Luye Pharma Group Ltd.
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- February 25, 2022
- Completion date
- November 4, 2023
- Enrollment
- 104 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.